Teva Pharmaceutical Industries ADR (TEVA-N) Analyst Research & Price Targets - The Globe and Mail

Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Current Target Price

High Target Price

Mean Target Price

Low Target Price

Median Target Price

Earnings Estimates

	Current Qtr03/2024	Next Qtr06/2024	Fiscal Yr12/2024	Fiscal Yr12/2025
Average Estimate	0.49	0.56	2.28	2.51
Number of Estimates	6	6	6	6
High Estimate	0.52	0.58	2.36	2.60
Low Estimate	0.46	0.53	2.21	2.39
Prior Year	0.37	0.54	2.46	2.28
Growth Rate Est. (year over year)	+32.43%	+3.70%	-7.32%	+10.09%

Earnings History - Surprises*

	Qtr Ending12/2023	Qtr Ending09/2023	Qtr Ending06/2023	Qtr Ending03/2023
Reported	$0.98	$0.58	$0.54	$0.37
Estimate	$0.73	$0.57	$0.52	$0.55
Difference	+0.25	+0.01	+0.02	-0.18
Surprise	+34.25%	+1.75%	+3.85%	-32.73%

* Earnings are based on GAAP income from continuing operations.

Average Analyst Ratings

3.80

3 Mths Ago10

4.11

2 Mths Ago9

4.33

1 Mth Ago9

4.33

Current9

Ratings Values:

Strong Buy5

Moderate Buy4

Hold3

Moderate Sell2

Strong Sell1

Ratings Breakdown

	3 Mths Ago	2 Mths Ago	1 Mth Ago	Current
# of Analysts:	10	9	9	9
	5	6	6	6
Holds	4	2	3	3
	1	1

Key:

Strong Buy

Moderate Buy

Hold

Moderate Sell

Strong Sell

More from The Globe

The close: Stocks higher as investors focus on Fed moves

The close: Major North American indexes rise as megacap tech stocks rally

Why this money manager is venturing back into emerging markets and adding more U.S. tech

How a Canadian pirate-clad pastor helped ignite Trump Media’s market frenzy

Activist investor targets Dye & Durham’s ‘underperformance and strategic missteps’ in letter to shareholders

The close: U.S. stocks fall as GDP report spreads rate-cut gloom; Alphabet surges 15% in post market

Fiera Capital’s largest shareholder looks to sell stake in company

The close: S&P 500 higher as markets weigh rising bond yields and upbeat U.S. earnings; TSX lower as rails slide